IP Library Granted Patent US 8,071,746
Granted Patent B2
US 8,071,746 · App. 12/497,443 · Granted Dec 6, 2011

Isolated nucleic acid molecule encoding a peptide or peptide analog comprising the SEQ ID No. 3

Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,746
App. No.
12/497,443
Granted
Dec 6, 2011
Kind
B2
Abstract

Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.

Claims (5)

1. An isolated nucleic acid molecule encoding a peptide or peptide analog comprising the amino acid sequence as set forth in SEQ ID NO: 3.

2. The isolated nucleic acid molecule of claim 1 , wherein the isolated nucleic acid molecule encodes the peptide or peptide analog set forth in SEQ ID NO: 3, promotes ATP-binding cassette transporter A1 (ABCA1)-dependent lipid efflux from cells and is substantially non-cytotoxic.

3. The isolated nucleic acid molecule of claim 1 , wherein the isolated nucleic acid molecule encodes a peptide or peptide analog of claim 1 and at least one additional peptide domain.

4. The isolated nucleic acid molecule of claim 3 , wherein the additional peptide domain comprises a heparin binding site, an integrin binding site, a P-selectin site, a TAT HIV sequence, a panning sequence, a penatratin sequence, a serum amyloid A (SAA) C-terminus sequence, a SAA N-terminus sequence, a LDL receptor sequence, a modified 18A sequence, an apoA-I Milano sequence, a 6×-His sequence, a lactoferrin sequence, or combinations of two or more thereof.

5. The isolated nucleic acid of claim 1 for use in the manufacture of an implant for treating or inhibiting a dyslipidemic or vascular disorder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2009
From: REMALEY, ALAN T.; DEMOSKY, STEPHEN J.; STONIK, JOHN A.; AMAR, MARCELE J.A.; NEUFELD, EDWARD B.; THOMAS, FAIRWELL; BREWER, H. BRYAN
To: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 022921/0557 →
Continuity (3)
Division 11577259
Provisional Application 60619392 · Oct 15, 2004
Related Publication 20090270331A1 · Oct 29, 2009